Colrain Capital LLC Has $10.45 Million Position in Medtronic PLC $MDT

Key Points

• Colrain Capital increased its Medtronic position by 26.1% in the second quarter, bringing its holdings to 132,354 shares valued at approximately $10.45 million. Institutional investors and hedge funds collectively own 82.06% of MDT.
• Analyst sentiment remains positive but mixed: Medtronic has a consensus “Moderate Buy” rating and an average price target of $98.83, while several firms recently lowered targets and UBS upgraded the stock to “Buy.”
• Medtronic slightly exceeded quarterly earnings and revenue expectations, with revenue up 9.9% year over year. The company also raised its quarterly dividend to $0.72 per share, though legal uncertainty and recent insider selling remain potential risks.

Colrain Capital LLC grew its position in Medtronic PLC (NYSE:MDT - Free Report) by 26.1% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 132,354 shares of the medical technology company's stock after acquiring an additional 27,404 shares during the period. Medtronic comprises about 3.5% of Colrain Capital LLC's portfolio, making the stock its 15th largest holding. Colrain Capital LLC's holdings in Medtronic were worth $10,449,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of MDT. Monetary Solutions Ltd bought a new position in Medtronic during the fourth quarter worth about $27,000. Anfield Capital Management LLC raised its stake in Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company's stock valued at $27,000 after buying an additional 230 shares during the period. Acumen Wealth Advisors LLC bought a new stake in Medtronic in the fourth quarter valued at approximately $29,000. Imprint Wealth LLC acquired a new stake in shares of Medtronic in the third quarter valued at approximately $31,000. Finally, Basepoint Wealth LLC acquired a new stake in shares of Medtronic in the fourth quarter valued at approximately $32,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP Harry Skip Kiil sold 4,189 shares of Medtronic stock in a transaction on Monday, June 8th. The stock was sold at an average price of $80.44, for a total transaction of $336,963.16. Following the completion of the sale, the executive vice president owned 37,227 shares of the company's stock, valued at approximately $2,994,539.88. This trade represents a 10.11% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 0.26% of the stock is owned by insiders.

Analyst Ratings Changes

Several brokerages have recently commented on MDT. The Goldman Sachs Group reduced their target price on Medtronic from $84.00 to $83.00 and set a "neutral" rating for the company in a research note on Thursday, June 4th. Leerink Partners cut their price target on Medtronic from $117.00 to $104.00 and set an "outperform" rating for the company in a report on Thursday, June 4th. Rothschild & Co Redburn reduced their price objective on shares of Medtronic from $111.00 to $106.00 and set a "buy" rating for the company in a research report on Friday, June 5th. JPMorgan Chase & Co. decreased their price objective on shares of Medtronic from $100.00 to $86.00 and set a "neutral" rating on the stock in a report on Thursday, June 4th. Finally, UBS Group raised shares of Medtronic from a "neutral" rating to a "buy" rating and increased their price objective for the company from $85.00 to $100.00 in a research report on Tuesday, July 28th. Eighteen investment analysts have rated the stock with a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat.com, Medtronic currently has a consensus rating of "Moderate Buy" and a consensus target price of $98.83.

Trending Headlines about Medtronic

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Bank of America issued a bullish outlook ahead of earnings. The firm sees continued momentum from one of Medtronic’s key growth businesses and believes an additional catalyst could develop, potentially improving investor expectations before the results. Bank of America makes bullish call on 77-year-old healthcare stock
• Positive Sentiment: Medtronic is one dividend increase away from Dividend King status. The company has raised its dividend for 49 consecutive years and currently pays $0.72 per quarter, or $2.88 annually. Reaching the 50-year milestone could reinforce MDT’s appeal to income-focused and defensive investors. Medtronic plc is Closing in on Dividend King Status
• Neutral Sentiment: BTIG reaffirmed its “Buy” rating but set a $91 price target, below MDT’s recent trading level. The recommendation supports the long-term outlook, while the target suggests limited near-term upside at current levels. Other recent analyst targets have been mixed, with a reported median of $101. BTIG reaffirms buy rating on Medtronic
• Neutral Sentiment: Value-investor comparisons with Agilent Technologies and proxy-recommendation coverage may attract attention, but neither provides a clear new earnings or fundamental catalyst for MDT. MDT vs. A: Which Stock Should Value Investors Buy Now?
• Negative Sentiment: Medtronic faces a potential injunction in its Applied Medical case. An adverse ruling could create operational or legal uncertainty and represents a risk ahead of earnings. Medtronic faces potential injunction in Applied Medical case
• Negative Sentiment: Reported insider activity showed eight sales and no purchases over the past six months, while estimated CEO compensation increased year over year. These signals could weigh modestly on sentiment, although they do not necessarily indicate a change in Medtronic’s fundamentals. Medtronic CEO 2026 Pay Revealed

Medtronic Price Performance

Medtronic stock opened at $94.13 on Thursday. Medtronic PLC has a 12 month low of $73.31 and a 12 month high of $106.33. The stock's 50 day moving average is $83.88 and its 200-day moving average is $86.08. The company has a current ratio of 2.13, a quick ratio of 1.62 and a debt-to-equity ratio of 0.52. The company has a market capitalization of $120.49 billion, a price-to-earnings ratio of 25.24, a PEG ratio of 2.47 and a beta of 0.55.

Medtronic (NYSE:MDT - Get Free Report) last announced its earnings results on Wednesday, June 3rd. The medical technology company reported $1.55 earnings per share for the quarter, topping analysts' consensus estimates of $1.54 by $0.01. The company had revenue of $9.81 billion for the quarter, compared to analyst estimates of $9.62 billion. Medtronic had a return on equity of 14.51% and a net margin of 13.20%.The firm's quarterly revenue was up 9.9% compared to the same quarter last year. During the same quarter last year, the company earned $1.62 earnings per share. Medtronic has set its FY 2027 guidance at 5.900-6.000 EPS. Equities research analysts expect that Medtronic PLC will post 5.94 EPS for the current year.

Medtronic Increases Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, July 17th. Shareholders of record on Friday, June 26th were given a dividend of $0.72 per share. This represents a $2.88 annualized dividend and a yield of 3.1%. The ex-dividend date was Friday, June 26th. This is a positive change from Medtronic's previous quarterly dividend of $0.71. Medtronic's dividend payout ratio (DPR) is 77.21%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source